Summary | Mylan NV has been at the epicenter of M&A chatter --
both as a potential suitor and target -- for the better part of
a month, and some traders made big bets on the company's stock
ahead of the pharmaceutical company's unsolicited $28.9 billion
proposal to buy rival Perrigo Co. PLC.
blogs.wsj.com | 09 April 2015